Novo Nordisk A/S: all 1,444 studies

Page 10 of 15. Open to participants first (108), then studies with results posted, then the rest; newest registration first within each.

• Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes MellitusCompletedNCT01868529Phase 1
• Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male SubjectsCompletedNCT01866748Phase 1
• Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese SubjectsCompletedNCT01865331Phase 1
• Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 DiabetesCompletedNCT01865318Phase 1
• Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With DiabetesCompletedNCT01865305Phase 1
• Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 DiabetesCompletedNCT01865292Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin DegludecCompletedNCT01865279Phase 1
• Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational StudyCompletedNCT01862367
• Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy VolunteersCompletedNCT01848002Phase 1
• Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy VolunteersCompletedNCT01847989Phase 1
• An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 DiabetesCompletedNCT01846312
• A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With InhibitorsCompletedNCT01830712
• Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes MellitusCompletedNCT01821846
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy SubjectsCompletedNCT01809184Phase 1
• A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 DiabetesCompletedNCT01796366Phase 1
• A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 DiabetesCompletedNCT01789593Phase 1
• A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 YearsCompletedNCT01789086Phase 1
• A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 DiabetesCompletedNCT01780272Phase 1
• Treatment of Congenital Factor VII DeficiencyCompletedNCT01779921
• A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 DiabetesCompletedNCT01773798Phase 1
• A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing ProcessesCompletedNCT01766245Phase 1
• A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's DiseaseCompletedNCT01751152Phase 2
• Growth Response in Girls With Turner SyndromeCompletedNCT01734486Phase 4
• Long Term Effect of Somatropin in Subjects With Intrauterine Growth RetardationCompletedNCT01734447Phase 4
• A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 DiabetesCompletedNCT01730014Phase 1
• Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 DiabetesCompletedNCT01720303Phase 4
• Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 DiabetesCompletedNCT01720290Phase 4
• Induction of Puberty With 17-beta Estradiol in Girls With Turner SyndromeCompletedNCT01710696Phase 3
• Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes MellitusCompletedNCT01709929Phase 3
• Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy VolunteersCompletedNCT01707160Phase 1
• Safety and Efficacy of Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT01707134Phase 3
• A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone DeficiencyCompletedNCT01706783Phase 1
• Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal WomenCompletedNCT01705249Phase 4
• A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin GlargineCompletedNCT01704417Phase 1
• Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 DiabetesCompletedNCT01704378Phase 4
• Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone DeficiencyTerminatedNCT01698944Phase 4
• Efficacy of Repaglinide in Subjects With Type 2 DiabetesCompletedNCT01698931Phase 4
• Comparison of Two Insulin Aspart Formulations in Healthy VolunteersCompletedNCT01698697Phase 1
• Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 DiabetesCompletedNCT01697657Phase 3
• Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth RetardationCompletedNCT01697644Phase 4
• Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01697631Phase 4
• Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01697618Phase 2
• An International Survey on Hypoglycaemia Among Insulin-treated Patients With DiabetesCompletedNCT01696266
• Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia ACompletedNCT01692925Phase 1
• Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male SubjectsCompletedNCT01690169Phase 1
• An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)TerminatedNCT01689025Phase 1
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 DiabetesCompletedNCT01686945Phase 1
• A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 DiabetesCompletedNCT01682902Phase 1
• Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 DiabetesCompletedNCT01650129Phase 3
• Safety and Efficacy of Insulin Aspart in Type 2 DiabetesCompletedNCT01649570Phase 4
• A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid ArthritisCompletedNCT01647451Phase 2
• A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MethotrexateTerminatedNCT01636843Phase 2
• A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa BiologicsTerminatedNCT01636817Phase 2
• A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia SubjectsTerminatedNCT01631942Phase 1
• French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic PatientsCompletedNCT01628341
• A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy SubjectsCompletedNCT01623375Phase 1
• Safety and Tolerability of Liraglutide in Healthy Japanese VolunteersCompletedNCT01620476Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese VolunteersCompletedNCT01620463Phase 1
• Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy JapaneseCompletedNCT01620450Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese SubjectsCompletedNCT01620437Phase 1
• Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 DiabetesCompletedNCT01620424Phase 1
• Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy VolunteersCompletedNCT01620333Phase 1
• Pharmacoscintigraphic Investigation of NN9924 in Healthy Male SubjectsCompletedNCT01619345Phase 1
• A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 DiabetesCompletedNCT01618188Phase 1
• Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 DiabetesCompletedNCT01615978Phase 1
• First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid ArthritisCompletedNCT01611688Phase 1
• Effect of Repaglinide on Postprandial Lipemia in Type 2 DiabetesCompletedNCT01605773Phase 4
• Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner SyndromeCompletedNCT01604161
• A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy VolunteersCompletedNCT01603342Phase 1
• Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic FeverCompletedNCT01601613Phase 2
• Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture ReconstructionCompletedNCT01601457Phase 2
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy SubjectsCompletedNCT01597713Phase 1
• Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy WomenCompletedNCT01596010Phase 1
• A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 DiabetesCompletedNCT01590836Phase 1
• Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With InhibitorsCompletedNCT01586936
• Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin AnaloguesCompletedNCT01585506
• French National Registry of Adults With Growth Hormone Deficiency Treated With SomatropinCompletedNCT01580605
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing SurgeryCompletedNCT01579968
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical PracticeCompletedNCT01579955
• French National Registry of Children Born Small for Gestational Age Treated With SomatropinCompletedNCT01578135
• Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male SubjectsCompletedNCT01572753Phase 1
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral HaemorrhageCompletedNCT01566786Phase 2
• Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 DiabetesCompletedNCT01565733
• Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid ArthritisCompletedNCT01565408Phase 1
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell TransplantationTerminatedNCT01564563Phase 2
• Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone DeficiencyCompletedNCT01563926Phase 3
• Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma PatientsCompletedNCT01563523Phase 2
• Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy VolunteersCompletedNCT01563471Phase 1
• Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver TransplantationCompletedNCT01563458Phase 2
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral HaemorrhageCompletedNCT01563445Phase 2
• Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult PatientsCompletedNCT01562834Phase 4
• Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial HepatectomyCompletedNCT01562821Phase 2
• Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding StateCompletedNCT01562587Phase 1
• Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart DiseaseCompletedNCT01562574Phase 3
• Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 DiabetesCompletedNCT01562561Phase 3
• Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding StateCompletedNCT01562457Phase 1
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell TransplantationCompletedNCT01562158Phase 2
• Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated BleedingTerminatedNCT01561950Phase 1
• Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin TreatmentCompletedNCT01561937Phase 1
• Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of ThromboelastographyCompletedNCT01561924Phase 1

← Novo Nordisk A/S overview and focus areas